Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437507 | 0.92 | TLR8 (0.45) | TLR8STING1KMT2ANPC1JAK2 | |
| Bromide SCHEMBL19437532 | 0.85 | KMT2A (0.49) | TLR8STING1KMT2AJAK2JAK1 | |
| SCHEMBL19437587 | 0.84 | TLR8 (0.42) | TLR8STING1JAK2JAK1TYK2 | |
| SCHEMBL22136271 | 0.84 | TLR7 (0.43) | TLR8STING1 | |
| SCHEMBL19437481 | 0.84 | STING1 (0.59) | TLR8STING1 | |
| Bromide SCHEMBL19436512 | 0.83 | KMT2A (0.52) | TLR8STING1KMT2AJAK2JAK1 | |
| SCHEMBL19437508 | 0.81 | STING1 (0.55) | TLR8STING1 | |
| SCHEMBL19437547 | 0.79 | STING1 (0.44) | TLR8STING1 | |
| SCHEMBL19437536 | 0.79 | STING1 (0.43) | TLR8STING1KMT2ANPC1JAK2 | |
| SCHEMBL22857821 | 0.79 | POLB (0.41) | TLR8STING1KMT2ANPC1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| EP-3440072-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | ARGLU1, G3BP1, G3BP2 | TLR8 3263/4885STING1 2510/4885KMT2A 2117/4885 |
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | ARGLU1, G3BP1, G3BP2 | TLR8 3263/4885STING1 2510/4885KMT2A 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.